What is Sandstone Diagnostics?
Founded in 2012, Sandstone Diagnostics emerged from the expertise of government scientists at Sandia National Laboratories. The company's core mission is to democratize access to high-quality laboratory testing by developing portable centrifuge technology that can be utilized at the point of care. Sandstone has actively engaged in critical health initiatives, including participation in the Stanford StartX Med COVID-19 Task Force, aimed at providing essential solutions for the prevention, diagnosis, and treatment of infectious diseases. Furthermore, its membership in StartUp Health underscores its commitment to transforming global health through ambitious 'moonshots,' addressing pandemics and other pressing health challenges.
How much funding has Sandstone Diagnostics raised?
Sandstone Diagnostics has raised a total of $398K across 2 funding rounds:
Debt
$150K
Debt
$248K
Debt (2020): $150K with participation from PPP
Debt (2021): $248K led by PPP
Key Investors in Sandstone Diagnostics
PPP
Public-Private Partnership
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Sandstone Diagnostics?
With its recent large-scale, late-stage funding, Sandstone Diagnostics is poised to accelerate the commercialization and widespread adoption of its innovative diagnostic solutions. The strategic investment signals strong confidence from backers in the company's technology and its potential to disrupt traditional laboratory testing models. Expect Sandstone to focus on scaling its manufacturing capabilities, expanding its market reach, and potentially forging new partnerships to integrate its technology into diverse healthcare settings, thereby fulfilling its vision of ubiquitous, patient-centric lab testing.
See full Sandstone Diagnostics company page
